|
1
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Didier DK, Schiffenbauer J, Woulfe SL,
Zacheis M and Schwartz BD: Characterization of the cDNA encoding a
protein binding to the major histocompatibility complex class II Y
box. Proc Natl Acad Sci USA. 85:7322–7326. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eliseeva IA, Kim ER, Guryanov SG,
Ovchinnikov LP and Lyabin DN: Y-box-binding protein 1 (YB-1) and
its functions. Biochemistry (Mosc). 76:1402–1433. 2011. View Article : Google Scholar
|
|
4
|
Bargou RC, Jürchott K, Wagener C, Bergmann
S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B,
et al: Nuclear localization and increased levels of transcription
factor YB-1 in primary human breast cancers are associated with
intrinsic MDR1 gene expression. Nat Med. 3:447–450. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Janz M, Harbeck N, Dettmar P, Berger U,
Schmidt A, Jürchott K, Schmitt M and Royer HD: Y-box factor YB-1
predicts drug resistance and patient outcome in breast cancer
independent of clinically relevant tumor biologic factors HER2, uPA
and PAI-1. Int J Cancer. 97:278–282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mo D, Fang H, Niu K, Liu J, Wu M, Li S,
Zhu T, Aleskandarany MA, Arora A, Lobo DN, et al: Human helicase
RECQL4 drives cisplatin resistance in gastric cancer by activating
an AKT-YB1-MDR1 signaling pathway. Cancer Res. 76:3057–3066. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khanna P, Chua PJ, Bay BH and Baeg GH: The
JAK/STAT signaling cascade in gastric carcinoma (Review). Int J
Oncol. 47:1617–1626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kiu H and Nicholson SE: Biology and
significance of the JAK/STAT signalling pathways. Growth Factors.
30:88–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Catlett-Falcone R, Dalton WS and Jove R:
STAT proteins as novel targets for cancer therapy. Signal
transducer an activator of transcription. Curr Opin Oncol.
11:490–496. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Z, Si X, Xu A, Meng X, Gao S, Qi Y,
Zhu L, Li T, Li W and Dong L: Activation of STAT3 in human gastric
cancer cells via interleukin (IL)-6-type cytokine signaling
correlates with clinical implications. PLoS One. 8:e757882013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giraud AS, Menheniott TR and Judd LM:
Targeting STAT3 in gastric cancer. Expert Opin Ther Targets.
16:889–901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim DY, Cha ST, Ahn DH, Kang HY, Kwon CI,
Ko KH, Hwang SG, Park PW, Rim KS and Hong SP: STAT3 expression in
gastric cancer indicates a poor prognosis. J Gastroenterol Hepatol.
24:646–651. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deng JY, Sun D, Liu XY, Pan Y and Liang H:
STAT-3 correlates with lymph node metastasis and cell survival in
gastric cancer. World J Gastroenterol. 16:5380–5387. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang S, Chen M, Shen Y, Shen W, Guo H,
Gao Q and Zou X: Inhibition of activated Stat3 reverses drug
resistance to chemotherapeutic agents in gastric cancer cells.
Cancer Lett. 315:198–205. 2012. View Article : Google Scholar
|
|
17
|
Lim JP, Shyamasundar S, Gunaratne J,
Scully OJ, Matsumoto K and Bay BH: YBX1 gene silencing inhibits
migratory and invasive potential via CORO1C in breast cancer in
vitro. BMC Cancer. 17:2012017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
19
|
Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo
R, Ng TP, Kumar SD, Tsujimoto M and Bay BH: Y-Box-binding protein-1
is a promising predictive marker of radioresistance and
chemoradioresistance in nasopharyngeal cancer. Mod Pathol.
22:282–290. 2009. View Article : Google Scholar
|
|
20
|
Kosnopfel C, Sinnberg T and Schittek B:
Y-box binding protein 1 - a prognostic marker and target in tumour
therapy. Eur J Cell Biol. 93:61–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang J, Tan PH, Li KB, Matsumoto K,
Tsujimoto M and Bay BH: Y-box binding protein, YB-1, as a marker of
tumor aggressiveness and response to adjuvant chemotherapy in
breast cancer. Int J Oncol. 26:607–613. 2005.PubMed/NCBI
|
|
22
|
Stephanou A, Brar BK, Knight RA and
Latchman DS: Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and
Bcl-x promoters. Cell Death Differ. 7:329–330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nascimento AS, Peres LL, Fari AVS, Milani
R, Silva RA, da Costa Fernandes CJ, Peppelenbosch MP,
Ferreira-Halder CV and Zambuzzi WF: Phosphoproteome profiling
reveals critical role of JAK-STAT signaling in maintaining
chemoresistance in breast cancer. Oncotarget. 8:114756–114768.
2017. View Article : Google Scholar
|
|
24
|
Becker TM, Boyd SC, Mijatov B,
Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford
RF, Zhang XD, et al: Mutant B-RAF-Mcl-1 survival signaling depends
on the STAT3 transcription factor. Oncogene. 33:1158–1166. 2014.
View Article : Google Scholar
|
|
25
|
Saneja A, Khare V, Alam N, Dubey RD and
Gupta PN: Advances in P-glycoprotein-based approaches for
delivering anticancer drugs: Pharmacokinetic perspective and
clinical relevance. Expert Opin Drug Deliv. 11:121–138. 2014.
View Article : Google Scholar
|
|
26
|
Noguchi K, Katayama K, Mitsuhashi J and
Sugimoto Y: Functions of the breast cancer resistance protein
(BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 61:26–33. 2009.
View Article : Google Scholar
|
|
27
|
Zhang W, Meng Y, Liu N, Wen X-F and Yang
T: Insights into chemo-resistance of prostate cancer. Int J Biol
Sci. 11:1160–1170. 2015. View Article : Google Scholar :
|
|
28
|
Zhang G, Wang Z, Qian F, Zhao C and Sun C:
Silencing of the ABCC4 gene by RNA interference reverses multidrug
resistance in human gastric cancer. Oncol Rep. 33:1147–1154. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo T, Yu Y, Yip GW, Baeg GH, Thike AA,
Lim TK, Tan PH, Matsumoto K and Bay BH: Y-box binding protein 1 is
correlated with lymph node metastasis in intestinal-type gastric
cancer. Histopathology. 66:491–499. 2015. View Article : Google Scholar
|
|
30
|
Oda Y, Sakamoto A, Shinohara N, Ohga T,
Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M and Iwamoto Y: Nuclear
expression of YB-1 protein correlates with P-glycoprotein
expression in human osteosarcoma. Clin Cancer Res. 4:2273–2277.
1998.PubMed/NCBI
|
|
31
|
Koike K, Uchiumi T, Ohga T, Toh S, Wada M,
Kohno K and Kuwano M: Nuclear translocation of the Y-box binding
protein by ultraviolet irradiation. FEBS Lett. 417:390–394. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schittek B, Psenner K, Sauer B, Meier F,
Iftner T and Garbe C: The increased expression of Y box-binding
protein 1 in melanoma stimulates proliferation and tumor invasion,
antagonizes apoptosis and enhances chemoresistance. Int J Cancer.
120:2110–2118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yahata H, Kobayashi H, Kamura T, Amada S,
Hirakawa T, Kohno K, Kuwano M and Nakano H: Increased nuclear
localization of transcription factor YB-1 in acquired
cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol.
128:621–626. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jackson CB and Giraud AS: STAT3 as a
prognostic marker in human gastric cancer. J Gastroenterol Hepatol.
24:505–507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Joo MK, Park JJ and Chun HJ: Recent
updates of precision therapy for gastric cancer: Towards optimal
tailored management. World J Gastroenterol. 22:4638–4650. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong W, Wang L, Yao JC, Ajani JA, Wei D,
Aldape KD, Xie K, Sawaya R and Huang S: Expression of activated
signal transducer and activator of transcription 3 predicts
expression of vascular endothelial growth factor in and angiogenic
phenotype of human gastric cancer. Clin Cancer Res. 11:1386–1393.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fujii T, Seki N, Namoto-Matsubayashi R,
Takahashi H, Inoue Y, Toh U, Kage M and Shirouzu K: YB-1 prevents
apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast
cancer cells. Future Oncol. 5:153–156. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng J, Liang H, Zhang R, Sun D, Pan Y,
Liu Y, Zhang L and Hao X: STAT3 is associated with lymph node
metastasis in gastric cancer. Tumour Biol. 34:2791–2800. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guo TT, Yu YN, Yip GW, Matsumoto K and Bay
BH: Silencing the YB-1 gene inhibits cell migration in gastric
cancer in vitro. Anat Rec (Hoboken). 296:891–898. 2013. View Article : Google Scholar
|
|
41
|
Lee C, Dhillon J, Wang MY, Gao Y, Hu K,
Park E, Astanehe A, Hung MC, Eirew P, Eaves CJ, et al: Targeting
YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis
via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
Cancer Res. 68:8661–8666. 2008. View Article : Google Scholar : PubMed/NCBI
|
